Can NAC Help Fatty Liver? What Clinical Research Actually Shows

By Pharm Chidi, The Root-Cause Pharmacist® · Evidence overview, 6 October 2026

When someone asks me whether NAC can help with fatty liver, I start with the full picture. Fatty liver disease is often called metabolic dysfunction-associated steatotic liver disease (MASLD). NAC helps the body make glutathione, a compound involved in antioxidant defence, which is one reason researchers are interested in it. I see that as a promising area to explore while keeping expectations grounded in the human evidence.

Can NAC help fatty liver in Nigeria?

NAC is being studied for metabolic fatty liver disease, but current human research has not shown that it removes liver fat or reverses fibrosis. In Nigeria, ask a clinician about metabolic risks and fibrosis assessment before choosing a supplement. NAC cannot replace nutrition, activity or recommended medical follow-up; finished LIPO-NAC has not been tested for this outcome.

What does the research show?

Researchers have studied NAC because oxidative stress may play a role in MASLD. So far, the human evidence is mixed. A randomized, double-blind trial found changes in some oxidative, glycaemic and inflammatory markers, but no significant improvement in liver fat, liver enzymes or lipid profiles. Earlier trial evidence has not established a clear clinical benefit over placebo. I would not assume findings from one dose or population apply to every NAC product.

Animal studies and blood markers can point researchers in useful directions, but they cannot show that a supplement removes liver fat or reverses fibrosis in people. That distinction helps me explain where a product may fit without promising an outcome that has not been demonstrated.

My practical approach to liver health

If you have been told you have fatty liver, I encourage you to ask what it means for your own health and whether you need an assessment of liver fibrosis. Review blood glucose, blood pressure, lipids, weight and alcohol use with your clinician. Liver enzymes alone do not tell the whole story.

Where weight reduction is appropriate, a sustainable eating pattern and physical activity are central. Guidance indicates that losing around 3–5% of body weight can improve steatosis, while a larger change is usually needed for inflammation and fibrosis. Your goals should fit your circumstances and be agreed with your healthcare team.

Where does our LIPO-NAC fit?

We formulated NutriQure LIPO-NAC with 600 mg of NAC plus selenium and molybdenum per capsule. For someone interested in an NAC-based antioxidant supplement, it offers a straightforward way to include these ingredients in a wider wellness routine.

I would discuss it as a supplement alongside nutrition, activity and appropriate medical follow-up. The cited MASLD studies are not trials of our finished LIPO-NAC formula, so I cannot present it as a proven treatment for fatty liver disease. If you have a liver condition or take medicines, speak with your pharmacist or doctor about suitability and follow the pack directions.

Questions I suggest bringing to an appointment

• Do I need a fibrosis risk assessment or additional tests?
• Which metabolic risks should I address first?
• What changes are realistic for my circumstances?
• Could my medicines or supplements affect my liver or interact with treatment?

My takeaway: There are positive, practical steps you can take for liver health. Understand your risk factors, build habits you can sustain and agree a monitoring plan. Our LIPO-NAC is an NAC-based option to discuss within that wider plan, with realistic expectations about what the research shows.

See the current LIPO-NAC price in naira and stock status, and how to request batch documents or verify a registration claim. The number on a final product pack, if present, should be checked in the official NAFDAC register; we do not infer registration from an ingredient study.

Sources

1. Randomized trial of NAC in MASLD: liver and metabolic outcomes.
2. Systematic review of pharmacological interventions for NAFLD.
3. AASLD practice guidance on clinical assessment and management of NAFLD.
4. NIDDK: treatment for NAFLD and NASH.